Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia (INSPIRE)

NCT05785442 PHASE2 COMPLETED

The current study is an exploratory, phase IIa randomized clinical trial (RCT) aiming to evaluate if early presepsin increase coupled with early initiation of anakinra as an adjunct therapy to the standard-of-care treatment may improve outcomes of community-acquired pneumonia or hospital-acquired pneumonia.

Details

Lead sponsor	Hellenic Institute for the Study of Sepsis
Phase	PHASE2
Status	COMPLETED
Enrolment	60
Start date	Mon Mar 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Community-acquired Pneumonia
• Hospital-acquired Pneumonia

Interventions

• Anakinra Prefilled Syringe
• Placebo

Countries

Greece